The Biologicals and Vaccines Institute of Southern Africa (Biovac) is expanding its biopharmaceutical manufacturing footprint in Cape Town through a multi-vaccine project. The initiative includes technology transfer agreements for vaccine fill and finish manufacturing as well as the end-to-end scale-up of an internally developed Oral Cholera Vaccine (OCV). The project involves constructing a new green facility designed to manufacture up to 250 million vaccine doses per year, comprising a glass vial fill & finish suite, a drug substance suite for inactivated OCV, and a blow-fill-seal plastic line for fill & finish.
THE BIOLOGICALS AND VACCINES INSTITUTE OF SOUTHERN AFRICA LTD tenders
The Biologicals and Vaccines Institute of Southern Africa (Biovac), supported by IFC financing, is establishing a new vaccine manufacturing facility adjacent to its Cape Town operations. The project entails constructing a facility with a glass vial fill-and-finish suite, drug substance suite, and blow-fill-seal plastic line for producing vaccines including Pneumococcal Conjugate Vaccine (PCV), Meningococcal Vaccine (Mening-X), Inactivated Polio Vaccine (IPV), Oral Cholera Vaccine (OCV), and Rotavirus Vaccine.
About THE BIOLOGICALS AND VACCINES INSTITUTE OF SOUTHERN AFRICA LTD tenders
THE BIOLOGICALS AND VACCINES INSTITUTE OF SOUTHERN AFRICA LTD publishes tenders, requests for quotation and requests for proposal for goods, services and works. Most bids require CSD registration, tax compliance and a B-BBEE certificate or affidavit, and many add sector-specific registrations and proof of experience. TendersHQ lists every live THE BIOLOGICALS AND VACCINES INSTITUTE OF SOUTHERN AFRICA LTD tender in one place, across every sector and province, and summarises the requirements so you can decide quickly whether to bid.